Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)

Asim Amin; Elizabeth R. Plimack; Marc S. Ernstoff; Lionel D. Lewis; Todd M. Bauer; David F. McDermott; Michael Carducci; Christian Kollmannsberger; Brian I. Rini; Daniel Y.C. Heng; Jennifer Knox; Martin H. Voss; Jennifer Spratlin; Elmer Berghorn; Lingfeng Yang; Hans J. Hammers

doi:10.1186/s40425-019-0559-3

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)

Asim Amin
, Elizabeth R. Plimack
, Marc S. Ernstoff
, Lionel D. Lewis
, Todd M. Bauer
, David F. McDermott
, Michael Carducci
, Christian Kollmannsberger
, Brian I. Rini
, Daniel Y.C. Heng
, Jennifer Knox
, Martin H. Voss
, Jennifer Spratlin
, Elmer Berghorn
, Lingfeng Yang
, Hans J. Hammers

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

2 Scopus citations

Abstract

Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable." should be replaced with "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable." (3.0% instead of 0.3%). The publisher apologizes for any inconvenience caused by this error.

Original language	English (US)
Article number	73
Journal	Journal for immunotherapy of cancer
Volume	7
Issue number	1
DOIs	https://doi.org/10.1186/s40425-019-0559-3
State	Published - Mar 14 2019

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Molecular Medicine
Oncology
Pharmacology
Cancer Research

Access to Document

10.1186/s40425-019-0559-3

Fingerprint

Dive into the research topics of 'Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)'. Together they form a unique fingerprint.

Cite this

Amin, A., Plimack, E. R., Ernstoff, M. S., Lewis, L. D., Bauer, T. M., McDermott, D. F., Carducci, M., Kollmannsberger, C., Rini, B. I., Heng, D. Y. C., Knox, J., Voss, M. H., Spratlin, J., Berghorn, E., Yang, L., & Hammers, H. J. (2019). Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0). Journal for immunotherapy of cancer, 7(1), Article 73. https://doi.org/10.1186/s40425-019-0559-3

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0). / Amin, Asim; Plimack, Elizabeth R.; Ernstoff, Marc S. et al.
In: Journal for immunotherapy of cancer, Vol. 7, No. 1, 73, 14.03.2019.

Research output: Contribution to journal › Comment/debate › peer-review

Amin, A, Plimack, ER, Ernstoff, MS, Lewis, LD, Bauer, TM, McDermott, DF, Carducci, M, Kollmannsberger, C, Rini, BI, Heng, DYC, Knox, J, Voss, MH, Spratlin, J, Berghorn, E, Yang, L & Hammers, HJ 2019, 'Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)', Journal for immunotherapy of cancer, vol. 7, no. 1, 73. https://doi.org/10.1186/s40425-019-0559-3

Amin A, Plimack ER, Ernstoff MS, Lewis LD, Bauer TM, McDermott DF et al. Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0). Journal for immunotherapy of cancer. 2019 Mar 14;7(1):73. doi: 10.1186/s40425-019-0559-3

Amin, Asim ; Plimack, Elizabeth R. ; Ernstoff, Marc S. et al. / Correction to : Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0). In: Journal for immunotherapy of cancer. 2019 ; Vol. 7, No. 1.

@article{30fee8bf416b4c5e8ba302a4113fbe3a,

title = "Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)",

abstract = "Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence {"}Two (6.1\%) patients achieved a complete response, 16 (48.5\%) achieved a partial response, 11 (33.3\%) had stable disease, one (0.3\%) had progressive disease, and in three patients (9.1\%), response was undeterminable.{"} should be replaced with {"}Two (6.1\%) patients achieved a complete response, 16 (48.5\%) achieved a partial response, 11 (33.3\%) had stable disease, one (3.0\%) had progressive disease, and in three patients (9.1\%), response was undeterminable.{"} (3.0\% instead of 0.3\%). The publisher apologizes for any inconvenience caused by this error.",

author = "Asim Amin and Plimack, \{Elizabeth R.\} and Ernstoff, \{Marc S.\} and Lewis, \{Lionel D.\} and Bauer, \{Todd M.\} and McDermott, \{David F.\} and Michael Carducci and Christian Kollmannsberger and Rini, \{Brian I.\} and Heng, \{Daniel Y.C.\} and Jennifer Knox and Voss, \{Martin H.\} and Jennifer Spratlin and Elmer Berghorn and Lingfeng Yang and Hammers, \{Hans J.\}",

note = "Publisher Copyright: {\textcopyright} 2019 The Author(s).",

year = "2019",

month = mar,

day = "14",

doi = "10.1186/s40425-019-0559-3",

language = "English (US)",

volume = "7",

journal = "Journal for immunotherapy of cancer",

issn = "2051-1426",

publisher = "BMJ Publishing Group",

number = "1",

}

TY - JOUR

T1 - Correction to

T2 - Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)

AU - Amin, Asim

AU - Plimack, Elizabeth R.

AU - Ernstoff, Marc S.

AU - Lewis, Lionel D.

AU - Bauer, Todd M.

AU - McDermott, David F.

AU - Carducci, Michael

AU - Kollmannsberger, Christian

AU - Rini, Brian I.

AU - Heng, Daniel Y.C.

AU - Knox, Jennifer

AU - Voss, Martin H.

AU - Spratlin, Jennifer

AU - Berghorn, Elmer

AU - Yang, Lingfeng

AU - Hammers, Hans J.

PY - 2019/3/14

Y1 - 2019/3/14

N2 - Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable." should be replaced with "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable." (3.0% instead of 0.3%). The publisher apologizes for any inconvenience caused by this error.

AB - Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable." should be replaced with "Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable." (3.0% instead of 0.3%). The publisher apologizes for any inconvenience caused by this error.

UR - https://www.scopus.com/pages/publications/85062998201

UR - https://www.scopus.com/pages/publications/85062998201#tab=citedBy

U2 - 10.1186/s40425-019-0559-3

DO - 10.1186/s40425-019-0559-3

M3 - Comment/debate

C2 - 30871617

AN - SCOPUS:85062998201

SN - 2051-1426

VL - 7

JO - Journal for immunotherapy of cancer

JF - Journal for immunotherapy of cancer

IS - 1

M1 - 73

ER -

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: The CheckMate 016 study (Journal for ImmunoTherapy of Cancer (2018) 6 (109) DOI: 10.1186/s40425-018-0420-0)

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this